Preliminary analysis of a trial of pulse cyclophosphamide in IFN-β-resistant active MS

Journal of the Neurological Sciences

Volumn 223, Issue 1, 2004, Pages 73-79

  Smith, Derek ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Blinding; Controlled trials; Cyclophosphamide; Glucocorticoids; Immunosuppressive therapy; Interferon ; Methylprednisolone; MRI; Multiple sclerosis; Randomization; Treatment failure

Indexed keywords

BETA1 INTERFERON; CYCLOPHOSPHAMIDE; GADOLINIUM; METHYLPREDNISOLONE;

ADULT; ARTICLE; BLOOD SAMPLING; BRAIN TOMOGRAPHY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SINGLE BLIND PROCEDURE; TREATMENT FAILURE; URINALYSIS;

ADULT; BRAIN; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GADOLINIUM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS; SALVAGE THERAPY; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 3142630123     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2004.04.026     Document Type: Article

References (12)

1. Rudick R., Cohen J. Multiple sclerosis therapeutics. 2002;Martin Dunitz, London. Chapter 28
2. Gobbini M.I., Smith M.E., Richert N.D., et al. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J. Neuroimmunol. 99:1999;142-149
3. Edan G., Miller D., Clanet M., Confavreux C., Lyon-Caen O., Lubetzki C., et al. Therapeutic effect of mitoxantrone combined with methyprednisolone in MS: a randomized multicenter study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry. 62:1997;112-118
4. Miller D.H., Barkhof F., Berry I., Kappos L., Scotti G., Thompson A.J. MRI in monitoring the treatment of MS: concerted action guidelines. JNNP. 54:1991;683-688
5. Guttmann C.R., Kikinis R., Anderson M.C., et al. Quantitative follow-up of patients with multiple sclerosis using MRI: reproducibility. J. Magn. Reson. Imaging. 9:1999;509-518
6. Ettinger G.J., Grimson W.E.L., Lozano-Perez T. Proceedings of the IEEE Workshop on Biomedical Image analysis. 1994;297-306 IEEE Computer Society Press, Los Alamitos, CA
7. Wei X., Warfield S.K., Zou K.H., et al. Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J. Magn. Reson. Imaging. 15:2002;203-209
8. Warfield S.K., Kaus M., Jolesz F.A., Kikinis R. Adaptive, template moderated, spatially varying statistical classification. Med. Image Anal. 4:2000;43-55
9. Durelli, L. Platform Presentation, American Academy of Neurology, Annual Meeting. Neurology 2002 Supplement[S62.004/A493]
10. PRISMS Study Group and the University of British Columbia MS/MR Analysis Group: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 56(12):2001 (Jun 26);1620
11. Smith D.R., Balashov K.E., Hafler D.A., Khoury S.J., Weiner H.L. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann. Neurol. 42:1997;313-318
12. Rodriguez M., Lindsley M.D. Immunosuppression promotes CNS remyelination in chronic virus-induced demyelinating disease. Neurology. 42:1992;348-357